
Overview
Urteste is developing the world's first method for detecting multiple cancers from a single urine sample. This early cancer detection technology aims to enable effective treatment by identifying the disease at an early stage.
Financials
Revenue history (in k)
Filing timeliness
4 of 5 financial statements were filed late (the longest delay 83 days for 2025). All were audited by a statutory auditor.
- 202506/10/2026
- 202405/07/2025
- 202327/07/2024
- 202205/09/2023
- 202121/07/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 50.40
- High
- PLN 52.80
- Low
- PLN 46.00
- Volume
- 1.88K
- Avg. vol.
- 1.46K
- Market cap
- PLN 78.14M
- P/E ratio
- –
- EPS
- -PLN 2.37
- Shares outstanding
- 1.53M
- 52-week
- PLN 39.90 – 57.60
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLURTST00010
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 810.37 | USD 501.62k | USD 489.20k |
| Q1 2026 | – | USD -488.11k | USD -501.62k |
| Q4 2025 | – | USD -461.07k | USD -473.88k |
| Q3 2025 | – | USD -421.15k | USD -422.15k |
Results for Q3 2026:Nov 30, 2026
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Websites
- espicore.plEspiCore 2.0 – system wczesnego ostrzegania ESPICloudflare
Trademarks
The company holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2021.
| Mark | Protected until | |
|---|---|---|
| URTESTE (word) | Jan 22, 2031 |
Authorized Representatives
Manner of representation
In the case of a one-person management board as well as a multi-member management board, each member of the management board is authorised to make declarations within the scope of the company’s rights and obligations independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Sanctions and PEP
Sanctions
No matches (EU, UN, US, UK, MSWiA, World Bank)
PEP
No matches
Bank accounts
Registered as a VAT taxpayer on 2019-06-08.
67 1050 1764 1000 0090 8061 8250
66 1050 1764 1000 0090 8061 8268
44 1050 1764 1000 0090 8061 8276
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 29, 2021 | Transformation registered |
Public aid
11 public aid cases recorded, with a total value of $14,588,265.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Nov 21, 2024 | Aid for research and development projects: experimental development | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Nov 21, 2024 | Aid for research and development projects: industrial research | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Nov 21, 2024 | Aid for SMEs for innovation support | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $14,580,706.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-01-02 | NASTRO test – a low-cost, enzyme-based IVD test for diagnosing breast cancer in its early stages, international protection of industrial property rights for a new breast diagnostic marker, and acquisition and development of URTESTE S.A. team competencies in R&D and commercialisation | $2.9M$2,873,572 | European Funds for a Modern Economy | |
| 2023-05-10 | PANURI Test – a highly effective, low-cost enzyme-based IVD test for diagnosing pancreatic cancer in its early stages, and international protection of industrial property rights for inventions in the form of enzyme-based IVD tests for detecting other cancers. | $9.1M$9,103,773 | European Funds for a Modern Economy | |
| 2023-05-01 | Diagnostic test for detecting pancreatic cancer at an early stage of development. | $2.6M$2,586,802 | European Funds for a Modern Economy |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Scope Fluidics S.A. | $1,264,188.85 | scopefluidics.com | ||
| Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o. | $969,037.30 | kmptm.pl | ||
| Toxlab sp. z o.o. | $865,185.14 | toxlab.pl | ||
| Nanogroup S.A. | $843,099.47 | nanogroup.eu | ||
| Fileclo sp. z o.o. | $722,197.66 | fileclo.pl | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com | ||
| Human Biome S.A. | $583,508.16 | human-biome.com | ||
| Pharmena S.A. | $541,436.46 | pharmena.eu | ||
| Lbs-Laboratorium Badań Sądowych sp. z o.o. | $452,284.99 | lbs-laboratorium.pl | ||
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-11-17 | Share capital increase (152,608.00 PLN → 163,278.00 PLN) | |
| 2026-09-07 | Share capital increase (140,966.90 PLN → 152,608.00 PLN) | |
| 2023-06-07 | Share capital increase (114,028.00 PLN → 140,966.90 PLN) | |
| 2022-04-01 | Share capital increase (111,978.80 PLN → 114,028.00 PLN) | |
| 2021-08-12 | Share capital increase (102,458.80 PLN → 111,978.80 PLN) |
FAQ
Last updated: 2026-11-17